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Bacillus coagulans: a viable adjunct therapy for
relieving symptoms of rheumatoid arthritis






Background: Lactic acid-producing bacteria (LAB) probiotics demonstrate immunomodulating and anti-
inflammatory effects and the ability to lessen the symptoms of arthritis in both animals and humans. This
randomized, double-blind, placebo-controlled, parallel-design, clinical pilot trial was conducted to evaluate the
effects of the LAB probiotic preparation, Bacillus coagulans GBI-30, 6086, on symptoms and measures of functional
capacity in patients with rheumatoid arthritis (RA) in combination with pharmacological anti-arthritic medications.
Methods: Forty-five adult men and women with symptoms of RA were randomly assigned to receive Bacillus
coagulans GBI-30, 6086 or placebo once a day in a double-blind fashion for 60 days in addition to their standard
anti-arthritic medications. Arthritis activity was evaluated by clinical examination, the American College of
Rheumatology (ACR) criteria, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), and
laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
Results: Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant
improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale
(P = .046) vs placebo. Compared with placebo, Bacillus coagulans GBI-30, 6086 treatment resulted in greater
improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to
walk 2 miles, reach, and participate in daily activities. There were no treatment-related adverse events reported
throughout this study.
Conclusions: Results of this pilot study suggest that adjunctive treatment with Bacillus coagulans GBI-30, 6086 LAB
probiotic appeared to be a safe and effective for patients suffering from RA. Because of the low study population
size, larger trials are needed to verify these results.
Trial registration: ACTRN12609000435280
Background
Probiotics have been used to treat and prevent a wide
range of infectious and inflammatory diseases [1,2]. Of
particular interest are lactic acid bacteria (LAB) probio-
tics and their immunomodulating and anti-inflammatory
effects, which have been shown to lessen the symptoms
of arthritis [3-8].
Rheumatoid arthritis (RA) affects more than 1.3 mil-
lion American adults [9]. It commonly leads to signifi-
cant disability and compromises quality of life.
Pharmacological treatments for arthritis target the
inflammatory process by suppressing the host reaction.
Despite the number of effective pharmacological agents
available today, a substantial proportion of patients will
experience persistent, low-level disease activity [10].
This underscores the need for adjunctive therapies that
are safe and can help relieve the painful symptoms of
arthritis.
RA is an autoimmune disorder in which unchecked
immune and inflammatory responses cause articular
pain and eventually cartilage degradation and bone
destruction [11]. Disease develops when there is an
imbalance in the cytokine network, either from excess
production of pro-inflammatory cytokines or from * Correspondence: david@dmandelmd.com
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Evidence has shown that there is a relationship between
the gastrointestinal microbiota, the mucosal and sys-
temic immune responses, and the development of
arthritis [5,13,14]. LAB have been shown to significantly
downregulate proinflammatory cytokines (eg, IFN-g,I L -
12, TNF-a) without altering regulatory cytokines (eg,
IL-10, TGF-b) to cause anti-inflammatory effects that
alleviate RA symptoms [3,14-19]. Therefore, it might be
speculated that therapeutic strategies that aim to nor-
malize the gut microflora in order to maintain proper
gastrointestinal and immune system function may
downregulate the abnormal inflammatory response and
alleviate symptoms of RA.
GanedenBC
30(Bacillus coagulans GBI-30, 6086, Gane-
den Biotech, Inc., Mayfield Heights, OH) is a strain of
LAB that can withstand the low pH of stomach acid is
activated in the intestines to modulate the gut micro-
flora and the immune response [18-20]. The objective of
this pilot study was to evaluate the effects of Bacillus
coagulans GBI-30, 6086 on RA symptoms and the func-
tional ability of patients with RA when used in combina-
tion with pharmacological anti-rheumatic medications.
Methods
Study design
This was a randomized, double-blind, placebo-con-
trolled, parallel-design study of Bacillus coagulans GBI-
30, 6086 LAB probiotic as an adjunctive therapy for the
relief of symptoms of RA. The objective was to evaluate
the effects of Bacillus coagulans GBI-30, 6086 on RA
symptoms compared with placebo.
The treatment allocation scheme was generated and
assigned by a third party who did not have direct patient
contact. The treatment assignments were in sealed, tam-
per-proof, blinded envelopes and were handed out in
sequential fashion according to a computer-generated
randomization list. Study personnel did not have access
to the randomization scheme or blinding process. Col-
lected data were concealed in a pouch that remained
unopened until all results were submitted.
This study was registered with the Australian New
Zealand Clinical Trials Registry.
Patient population
Forty-five adult men and women with symptoms of RA
were included in the study. Sample size was determined
by power analysis. Subjects were recruited by the pri-
mary investigator from his daily practice and follow-up
visits were conducted at the practice.
Inclusion criteria included men and women with RA
for at least 1 year and up to 80 years of age. The criteria
for the diagnosis of RA included four or more of the fol-
lowing symptoms: 1) morning stiffness lasting at least 1
hour; 2) soft tissue swelling in 3 or more joint areas
observed by a physician; 3) swelling of the proximal
interphalangeal, metacarpophalangeal, or wrist joints; 4)
symmetric swelling; 5) rheumatoid nodules; 6) the pre-
sence of rheumatoid factor; and 7) radiographic erosions
and/or periarticular osteopenia in hand and/or wrist
joints. The first 4 criteria must have been present for at
least 6 weeks for inclusion in the study.
The exclusion criteria were pregnancy, chronic inflam-
matory bowel disease, kidney disease, liver disease, expo-
sure to > 10 mg/day of prednisolone, or treatment with
other probiotic products.
Patients read and signed an approved consent form
prior to enrollment in the study. The study protocol
and test product(s) information were approved by an
Institutional Review Board (IRB; Schulman Associates,
Cincinnati, OH) prior to the beginning of the study.
Study treatment
Patients in each group underwent a baseline physical
assessment and then were randomized in a double-blind
manner to receive either placebo or 1 caplet of Bacillus
coagulans GBI-30, 6086 (2 billion CFU) daily at approxi-
mately the same time each day, regardless of meals, for
a period of 60 days. The probiotic preparation includes
Bacillus coagulans GBI-30, 6086, green tea extract,
methylsulfonylmethane, and vitamins and minerals
(including vitamins A, B, C, D, E, folic acid, and sele-
nium). The matching placebo contained microcrystalline
cellulose. Adherence to the study protocol was deter-
mined by caplet count at each examination.
Patient assessment
The 45 men and women enrolled in the study were ran-
domly assigned to receive Bacillus coagulans GBI-30,
6086 or placebo once a day for 60 days. Patients were
examined at the primary investigator’s practice at base-
line, at 30 days, and at 60 days to assess symptoms and
measures of disease activity. Blood draws were per-
formed at each visit. The primary outcome was change
from baseline compared with the end of the study per-
iod obtained by the American College of Rheumatology
(ACR) [21] criteria questionnaire and the Stanford
Health Assessment Questionnaire Disability Index
(HAQ-DI) [22]. Outcomes were classified as “global”
(sensitive to change in clinical trials) and “individual”
(relatively insensitive to change in clinical trials). The
global outcomes included patients’ global assessment,
pain assessment, and disability assessment, as well as
physicians’ global assessment, assessment of total painful
joints out of 68 joints assessed, total swollen joints out
of 66 joints assessed, and erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) levels from ACR
and pain from the HAQ-DI. Individual outcomes were
assessed based on hygiene (ability to wash and dry the
body, take a tub bath, get on and off the toilet) and the
a b i l i t yt od r e s sa n dg r o o m ,a r i s e ,e a t ,w a l k2m i l e s ,
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adverse events were reported directly to the sponsor and
IRB by each investigator.
Statistical analysis
For each outcome, summary measures based on the
change from baseline to 60 days were obtained for each
group and group differences were tested. For global vari-
ables, each response was normalized (using Blom scores)
and the difference (end minus baseline) was obtained to
p r o v i d eac h a n g es c o r e .AS t u d e n t ’s t test was per-
formed to test for a difference in the mean change score
between subjects randomized to Bacillus coagulans GBI-
30, 6086 vs placebo. The effectiveness of the normaliza-
tion was checked via the Shapiro-Wilk test for normality
and the folded form F statistic to test for equality of
group variances. For individual outcomes, due to their
discrete nature, we utilized the binary indicator of a dif-
ference score of less than zero, indicating some
improvement in the score for the item. Barnard’se x a c t
unconditional test was used to compare the proportions
who improved in the Bacillus coagulans GBI-30, 6086
group vs placebo for each individual scale. Two-sided
P < .05 was considered statistically significant. Ninety-
five percent confidence intervals were computed for the
group difference for each outcome. For continuous out-
comes, confidence intervals for mean differences were
obtained based on a t test for normalized scores. For
binary outcomes, exact confidence intervals for the dif-
ference in proportions were computed.
Analyses were performed using SAS Version 8.0 (SAS
System, SAS Institute, Cary, NC) and StatXact Version
4.0 (Cytel Software Corporation, Cambridge, MA).
Results
Forty-five men and women who had RA for at least 1
year were enrolled in the study and randomly assigned
to receive Bacillus coagulans GBI-30, 6086 or placebo
once a day for 60 days (Figure 1). The majority of sub-
jects were female (81.8%) and all were Caucasian. Sub-
jects included in the study were between 36 and 82
years of age. The average age was 62.5 years. Although
subjects over the age of 80 were excluded from the
study because many subjects past this age have multiple
health issues that might impact their participation or
end results, 2 patients over the age of 80 were included
b e c a u s et h e ym e ta l lo t h e rs t u d yc r i t e r i aa n dw e r ei n
good overall health. The subjects’ standard of care for
RA was not altered during the course of the study. Most
subjects were taking and continued to take disease mod-
ifying antirheumatic drugs (DMARDs) (17 in the pla-
cebo group and 18 in the study treatment group) and 5
subjects continued to take non-steroidal anti-inflamma-
tory drugs (NSAIDs) (3 in the placebo group and 2 in
the study treatment group). Four subjects were not
taking medication for RA (3 in the placebo group and 1
in the treatment group). One subject developed an
upper respiratory infection (URI) and was started on
antibiotics, so the study treatment was discontinued.
This subject did not return for further visits and was,
therefore, excluded from analyses. Although this was
not an intent-to-treat analysis due to the 1 subject who
discontinued treatment, each study group included 22
patients for analysis.
Efficacy
Subjects who received Bacillus coagulans GBI-30, 6086
experienced borderline statistically significant improve-
ment from baseline in the Patient Pain Assessment
score (P = .052) and statistically significant improvement
from baseline in the Pain Scale (P = .046) compared
with subjects randomized to receive placebo. Bacillus
coagulans GBI-30, 6086 treatment resulted in greater
improvement in patient global assessment, patient self-
assessed disability, and reduction in total CRP (Table 1).
There were no significant differences in the physician
global assessment or physician assessment of painful
and swollen joints. For the HAQ individual disability
scores, the ability to walk 2 miles was marginally signifi-
cant (P = .072) and the ability to reach was not quite
significant (P = .11) (Table 2). Bacillus coagulans GBI-
30, 6086 also outperformed placebo for improvement in
the ability to participate in daily activities.
Eight subjects in the Bacillus coagulans GBI-30, 6086
group met ACR 20 criteria vs 6 subjects in the placebo
group. See Table 3 for an analysis of each group.
Safety
There were no serious adverse reactions reported
throughout this study. The treatment group reported 4
adverse events including shingles, poison ivy, a cold, and
leg edema, all of which were deemed unrelated to the
study treatment. The placebo group reported 3 adverse
events including gastrointestinal reflux, URI, and urinary
tract infection (UTI).
Discussion
The potential role of the intestinal microflora in modu-
lating immune responses has led to an interest in using
probiotics as preventive and therapeutic interventions.
For example, it has been shown that the enteric micro-
flora impact intestinal inflammatory responses and may
contribute to the articular inflammatory characteristics
of arthritis [13].
Rheumatoid arthritis is an autoimmune disease char-
acterized by a loss of tolerance to autoantigens (self
antigens), which triggers an inflammatory immune
response that causes joint damage and functional
impairment [23]. It has been speculated that infection
by microbial pathogens may trigger autoimmune reac-
tions through cross-reactivity, as environmental
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[23]. Changes to the normal gastrointestinal microflora
and dysregulation of the mucosal immune response to
these pathogens may contribute to the development of
autoimmune diseases such as RA [23]. This possibility
has led investigators to evaluate the efficacy of probio-
tics for alleviating RA symptoms through modulation of
the aberrant inflammatory autoimmune response.
Several preclinical studies have evaluated the effects of
various strains of LAB probiotics on symptoms and clin-
ical markers of arthritis. In one study [3], there was a
statistically significant decrease in inflammation over 1
month in rats fed yogurt containing Lactobacillus GG
(LGG) compared with rats fed plain yogurt or milk (P <
.05). An earlier study [18] found that Lactobacillus casei
reduced the incidence and development of collagen-
induced arthritis in mice and downregulated the cellular
and humoral immune responses to collagen in a dose-
dependent manner. More recently, a study in rats with
collagen-induced arthritis demonstrated that oral admin-
istration of L casei for 12 weeks reduced signs of arthri-
tis, lymphocyte infiltration into the joint, and
Figure 1 Study flowchart.
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animals [15]. In addition, rats receiving Lc a s e ihad
lower levels of proinflammatory cytokines and reduced
T cell proliferation, as well as increased production of
the anti-inflammatory cytokine IL-10. Other studies
have reported similar improvements in measures of
arthritis after administration of Lactobacillus fermentum
[16] and Lactobacillus delbrueckii [17].
A pilot clinical study [5] evaluated the long-term
effects of LGG on symptoms of RA. In this double-blind
study, 21 patients with RA were randomized to receive
2 capsules of LGG or placebo twice daily for 12 months.
The mean number of tender and swollen joints
decreased from 8.3 to 4.6 in the LGG group and from
5.5 to 4.8 in the placebo group (P = .41). However, con-
sidering only the long-term effects from baseline to
12 months, the mean number of tender and swollen
joints decreased from 8.3 to 4.4 in the LGG group and
increased from 5.5 to 5.6 in the placebo group (P = .09).
RA activity was reduced in 71% of patients in the LGG
group vs 30% of patients in the placebo group (P = .15).
Although there were no statistical differences in clinical
or biochemical parameters, more patients in the LGG
group reported a greater feeling of well-being.
In the present study, patients with RA who received
Bacillus coagulans GBI-30, 6086 experienced borderline
statistically significant improvement from baseline in the
Patient Pain Assessment score (P = .052) and statisti-
cally significant improvement from baseline in the Pain
Scale (P = .046) vs placebo. Treatment with Bacillus
coagulans GBI-30, 6086 resulted in greater improvement
in patient global assessment, patient self-assessed
Table 1 Mean change in global outcomes from baseline to 60 days
Placebo/Bacillus coagulans GBI-30, 6086 Difference in Means (95% CI) P Value
a
Score 22/22 0.006 (-0.33, 0.35) .97
Pain 21/22 0.46 (0.01, 0.91) .046
Patient global 22/22 0.047 (-0.38, 0.47) .83
Patient pain 22/22 0.41 (-0.004, 0.82) .052
Patient disability 22/22 0.19 (-0.16, 0.54) .28
Physician global 22/22 0.019 (-0.62, 0.66) .95
Painful joints 22/22 -0.074 (-0.81, 0.66) .84
Swollen joints 22/22 0.011 (-0.62, 0.64) .97
ESR 21/21 -0.054 (-0.49, 0.38) .80
CRP 22/22 0.008 (-0.52, 0.53) .98
Score = the mean of the eight category scores in the HAQ.
ESR = erythrocyte sedimentation rate.
CRP = C-reactive protein.
aP values calculated using Student’s t test for group differences in the mean change scores from baseline to 60 days (95% confidence interval).
Table 2 Proportion of patients who improved in individual outcomes from baseline to 60 days
Placebo Bacillus coagulans GBI-30, 6086




Arising 3/22 0.14 4/21 0.19 -0.054
(-0.36, 0.24)
.71
Walking 2 miles 2/22 0.091 7/22 0.32 -0.23
(-0.51, 0.09)
.072
Daily activities 2/22 0.091 4/22 0.18 -0.091
(-0.38, 0.21)
.53
Dressing and grooming 4/22 0.18 4/22 0.18 0
(-0.30, 0.30)
1.0
Eating 6/22 0.27 4/22 0.18 0.09
(-0.22, 0.39)
.53
Hygiene 2/22 0.091 2/22 0.091 0
(-0.28, 0.28)
1.0
Reach 4/22 0.18 9/22 0.41 -0.23
(-0.52, 0.09)
.11
Grip 5/22 0.23 4/22 0.18 0.045
(-0.26, 0.35)
.81
aP values calculated using Barnard’s exact unconditional test to compare the proportion who improved in both groups for each individual scale.
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ability to walk 2 miles, reach, and participate in daily
activities steadily improved over the 60 days; however,
these results did not reach statistical significance. The
ability to arise, dress and groom, eat, grip, and maintain
hygiene were similar between the 2 treatment groups.
T h eo v e r a l lr e s u l t so ft h i sp i l o ts t u d ys u p p o r tar o l ef o r
Bacillus coagulans GBI-30, 6086 as adjunctive therapy
for inflammatory diseases, as well as affirm the patho-
physiological connection between the gut microflora, the
mucosal immune system, and arthritic diseases.
Bacillus coagulans GBI-30, 6086 is a gram-positive,
spore-forming, aerobic to microaerophilic LAB bacillus
[24] that has a demonstrated ability to improve gastroin-
testinal health. To be effective, probiotics must survive
gastric and bile acids [25] in order to reach the intest-
inal tract, colonize the host epithelium, and exert a ben-
eficial effect [26]. Most LAB probiotics are inactivated
by bile and low gastric pH, whereas Bacillus coagulans
GBI-30, 6086 cultures are protected by a hardened layer
of organic spore coating that can withstand low gastric
pH for delivery to the more favorable environment of
the small intestine [20,25,27].
Although still controversial, evidence has suggested a
possible causal link between gut microbes and systemic
inflammatory disorders [5]. Once in the intestines,
Bacillus coagulans GBI-30, 6086 is activated and releases
anti-inflammatory molecules or acts indirectly to eradi-
cate organisms in the gut responsible for the inflamma-
tory immune response. Activated Bacillus coagulans
GBI-30, 6086 produces bacteriocins [28] and lowers
local pH by producing L(+) lactic acid that, along with
competition for sites of mucosal adherence, works to
dislodge and eliminate any antagonizing microbes that
may be contributing to an inflammatory response. Bacil-
lus coagulans GBI-30, 6086 also produces short-chain
fatty acids such as butyric acid, a compound known to
support the health and healing of cells in the small and
large intestines and to contribute to modulation of the
mucosal immune system.
W h i l es o m eR As t u d i e sf o l l o ws u b j e c t sf o ral o n g e r
period of time, it was the feeling of the investigators
that this study could be completed in a shorter time-
frame. Many patients show relief from symptoms within
60 days when treated with other traditional anti-inflam-
matory agents such as NSAIDs, and the same would be
expected of the study treatment. Therefore, subjects in
this pilot study were treated and evaluated for 60 days.
Conclusions
These study data suggest that Bacillus coagulans GBI-
30, 6086 LAB probiotic may be a safe and effective
adjunct therapy for the relief of symptoms of RA.
Because of the low study population size, large-scale,
controlled clinical trials are needed to confirm these
results.
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